FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982108766> ?p ?o ?g. }

• W2982108766 abstract "Abstract Background Robotic stereotactic ablative radiotherapy (SABR) is currently under investigation as a noninvasive treatment option for patients with renal cell carcinoma (RCC). For radiation therapy of RCC, tumor motion and the need for high ablative doses while preserving the remaining renal parenchyma is a challenge. We aimed to analyze the safety and efficacy of robotic radiosurgery in RCC in a specific difficult subgroup of patients with impaired renal function. Methods We retrospectively identified all patients with RCC, treated with robotic SABR and motion compensation in our institution between 2012 and 2017. Either single fraction SABR of 24 or 25 Gy or 3 fractions of 12 Gy prescribed to the 70% isodose line was applied. Local control, overall survival, radiation side effects were evaluated together with renal function and tumor motion. Results We analyzed data of 13 lesions treated in 10 patients with clear cell RCC and a mean age of 70.5 ± 13.6 years (range: 48–87). Prior to SABR, 8 patients underwent previous complete and/or partial nephrectomy, 7 patients presented with chronic kidney disease ≥ stage 3. The median of minimum, mean and maximum planning target volume doses were 23.2, 29.5 and 35.0 Gy for single fraction and 24.4, 42.5 and 51.4 Gy for the three fractions regime. Persistent local control by robotic SABR was achieved in 9 out of 10 patients (92.3% of all lesions) within a median follow-up period of 27 month (range: 15–54). One patient underwent nephrectomy due to progressive disease and sufficient renal function of the contralateral kidney. Renal function remained stable with a mean estimated glomerular filtration rate (eGFR) of 51.3 ± 19.7 ml/min at baseline and 51.6 ± 25.8 ml/min at follow-up. The largest respiratory-induced tumor motion was seen in superior-inferior direction, compensated by the CyberKnife with mean targeting errors of maximal 2.2 mm. Conclusions Robotic SABR is technically feasible for the treatment of RCC in preexisting kidney disease with good local tumor control at about 2 years follow-up. Robotic SABR with motion tracking offers a valid treatment option for patients, who are at increased risk for progression to end-stage renal disease due to partial nephrectomy or ablative techniques." @default.
• W2982108766 created "2019-11-01" @default.
• W2982108766 creator A5002520128 @default.
• W2982108766 creator A5021596074 @default.
• W2982108766 creator A5047048622 @default.
• W2982108766 creator A5052242253 @default.
• W2982108766 creator A5055306783 @default.
• W2982108766 creator A5069095104 @default.
• W2982108766 creator A5069412190 @default.
• W2982108766 creator A5069561430 @default.
• W2982108766 creator A5070280787 @default.
• W2982108766 creator A5079295628 @default.
• W2982108766 creator A5079543964 @default.
• W2982108766 creator A5087915335 @default.
• W2982108766 date "2019-10-21" @default.
• W2982108766 modified "2023-10-01" @default.
• W2982108766 title "Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function" @default.
• W2982108766 cites W1501578618 @default.
• W2982108766 cites W1529517881 @default.
• W2982108766 cites W1822261498 @default.
• W2982108766 cites W1994435768 @default.
• W2982108766 cites W2013411043 @default.
• W2982108766 cites W2033295431 @default.
• W2982108766 cites W2048195498 @default.
• W2982108766 cites W2072666370 @default.
• W2982108766 cites W2087887230 @default.
• W2982108766 cites W2097512974 @default.
• W2982108766 cites W2108935762 @default.
• W2982108766 cites W2110413848 @default.
• W2982108766 cites W2165948908 @default.
• W2982108766 cites W2310070191 @default.
• W2982108766 cites W2346399215 @default.
• W2982108766 cites W2587017049 @default.
• W2982108766 cites W2779215734 @default.
• W2982108766 cites W939733596 @default.
• W2982108766 doi "https://doi.org/10.1186/s12894-019-0531-z" @default.
• W2982108766 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6805546" @default.
• W2982108766 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31638979" @default.
• W2982108766 hasPublicationYear "2019" @default.
• W2982108766 type Work @default.
• W2982108766 sameAs 2982108766 @default.
• W2982108766 citedByCount "14" @default.
• W2982108766 countsByYear W29821087662020 @default.
• W2982108766 countsByYear W29821087662021 @default.
• W2982108766 countsByYear W29821087662022 @default.
• W2982108766 countsByYear W29821087662023 @default.
• W2982108766 crossrefType "journal-article" @default.
• W2982108766 hasAuthorship W2982108766A5002520128 @default.
• W2982108766 hasAuthorship W2982108766A5021596074 @default.
• W2982108766 hasAuthorship W2982108766A5047048622 @default.
• W2982108766 hasAuthorship W2982108766A5052242253 @default.
• W2982108766 hasAuthorship W2982108766A5055306783 @default.
• W2982108766 hasAuthorship W2982108766A5069095104 @default.
• W2982108766 hasAuthorship W2982108766A5069412190 @default.
• W2982108766 hasAuthorship W2982108766A5069561430 @default.
• W2982108766 hasAuthorship W2982108766A5070280787 @default.
• W2982108766 hasAuthorship W2982108766A5079295628 @default.
• W2982108766 hasAuthorship W2982108766A5079543964 @default.
• W2982108766 hasAuthorship W2982108766A5087915335 @default.
• W2982108766 hasBestOaLocation W29821087661 @default.
• W2982108766 hasConcept C106159729 @default.
• W2982108766 hasConcept C126322002 @default.
• W2982108766 hasConcept C126838900 @default.
• W2982108766 hasConcept C126894567 @default.
• W2982108766 hasConcept C141071460 @default.
• W2982108766 hasConcept C159641895 @default.
• W2982108766 hasConcept C162324750 @default.
• W2982108766 hasConcept C187625094 @default.
• W2982108766 hasConcept C19617505 @default.
• W2982108766 hasConcept C2777472916 @default.
• W2982108766 hasConcept C2778560582 @default.
• W2982108766 hasConcept C2780091579 @default.
• W2982108766 hasConcept C2780227381 @default.
• W2982108766 hasConcept C2780387249 @default.
• W2982108766 hasConcept C2989005 @default.
• W2982108766 hasConcept C509974204 @default.
• W2982108766 hasConcept C71924100 @default.
• W2982108766 hasConcept C78795084 @default.
• W2982108766 hasConcept C85393063 @default.
• W2982108766 hasConcept C91602232 @default.
• W2982108766 hasConceptScore W2982108766C106159729 @default.
• W2982108766 hasConceptScore W2982108766C126322002 @default.
• W2982108766 hasConceptScore W2982108766C126838900 @default.
• W2982108766 hasConceptScore W2982108766C126894567 @default.
• W2982108766 hasConceptScore W2982108766C141071460 @default.
• W2982108766 hasConceptScore W2982108766C159641895 @default.
• W2982108766 hasConceptScore W2982108766C162324750 @default.
• W2982108766 hasConceptScore W2982108766C187625094 @default.
• W2982108766 hasConceptScore W2982108766C19617505 @default.
• W2982108766 hasConceptScore W2982108766C2777472916 @default.
• W2982108766 hasConceptScore W2982108766C2778560582 @default.
• W2982108766 hasConceptScore W2982108766C2780091579 @default.
• W2982108766 hasConceptScore W2982108766C2780227381 @default.
• W2982108766 hasConceptScore W2982108766C2780387249 @default.
• W2982108766 hasConceptScore W2982108766C2989005 @default.
• W2982108766 hasConceptScore W2982108766C509974204 @default.
• W2982108766 hasConceptScore W2982108766C71924100 @default.
• W2982108766 hasConceptScore W2982108766C78795084 @default.
• W2982108766 hasConceptScore W2982108766C85393063 @default.
• W2982108766 hasConceptScore W2982108766C91602232 @default.

• next